BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32564752)

  • 1. Neoadjuvant Strategies Before Radical Prostatectomy for High Risk Prostate Cancer in the Era of New Hormonal Agents.
    Tafuri A; Cerruto MA; Antonelli A
    Curr Drug Targets; 2021; 22(1):68-76. PubMed ID: 32564752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.
    Devos G; Devlies W; De Meerleer G; Baldewijns M; Gevaert T; Moris L; Milonas D; Van Poppel H; Berghen C; Everaerts W; Claessens F; Joniau S
    Nat Rev Urol; 2021 Dec; 18(12):739-762. PubMed ID: 34526701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Approaches Prior To Radical Prostatectomy.
    Ryan ST; Patel DN; Parsons JK; McKay RR
    Cancer J; 2020; 26(1):2-12. PubMed ID: 31977379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
    Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
    Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
    Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
    Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
    Graham LS; True LD; Gulati R; Schade GR; Wright J; Grivas P; Yezefski T; Nega K; Alexander K; Hou WM; Yu EY; Montgomery B; Mostaghel EA; Matsumoto AA; Marck B; Sharifi N; Ellis WJ; Reder NP; Lin DW; Nelson PS; Schweizer MT
    Prostate; 2021 May; 81(7):418-426. PubMed ID: 33755225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant hormonal therapy in carcinoma of the prostate.
    Lee HH; Warde P; Jewett MA
    BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
    Lam ET; Glodé LM
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
    Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
    J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
    McClintock TR; von Landenberg N; Cole AP; Lipsitz SR; Gild P; Sun M; Fletcher SA; Roghmann F; Menon M; Nguyen PL; Noldus J; Choueiri TK; Kibel AS; Trinh QD
    Ann Surg Oncol; 2019 Jan; 26(1):297-305. PubMed ID: 30430324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
    Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.
    Pietzak EJ; Eastham JA
    Curr Urol Rep; 2016 May; 17(5):37. PubMed ID: 26968417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.
    Dorff TB; Glode LM
    Curr Opin Urol; 2013 Jul; 23(4):366-71. PubMed ID: 23619581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neoadjuvant hormonal therapy for prostate cancer].
    Miki T; Kamoi K
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):927-33. PubMed ID: 11478141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
    Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
    Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
    Akaza H; Hirao Y; Labrie F; Soloway MS
    Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review.
    Devos G; Vansevenant B; De Meerleer G; Clinckaert A; Devlies W; Claessens F; Graefen M; Steuber T; Briganti A; de la Taille A; Van Poppel H; Joniau S
    World J Urol; 2021 Sep; 39(9):3177-3185. PubMed ID: 33580296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.